Skip to content

Effectiveness of the Selective Serotonin Reuptake Inhibitor,Citalopram (Cipralex), in Prurigo Nodularis

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00532519
Enrollment
Unknown
Registered
2007-09-20
Start date
Unknown
Completion date
Unknown
Last updated
2007-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prurigo Nodularis

Brief summary

Prurigo nodularis (PN) is a common dermatological disorder, manifested as scaly nodules which appear mainly on the extensor surfaces of the limbs. PN may appear secondarily to skin scratching in chronic hepatitis, liver cirrhosis, uremia, hypothyroidism etc. Nevertheless, in many cases no underlying physical disease is present. According to the literature, in fifty percent of the patients there is co-morbidity with depression, anxiety or somatoform disorders. We hypothesize that a group of these patients may benefit from antidepressant therapy.

Interventions

DRUGcitalopram (cipralex)

10-20 mg/day, for 12 weeks.

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years

Inclusion criteria

* prurigo nodularis * age: 18-70 years * agreed to participate

Exclusion criteria

* younger than 18 or older than 70 * pregnant or lactating women * chronic diseases: cancer, neurological disorders, diseases that are known to be associated with pruritus such as liver cirrhosis, uremia, etc. * sensitivity to cipralotam * psychosis, bi-polar disorder, substance addiction, use of antidepressant in the previous year * use of systemic therapies to prurigo nodularis such as thalidomide, cyclosporine

Countries

Israel

Contacts

Primary ContactLiran Horev, MD
LIRAN_CH@BEZEQINT.NETOO97226777111

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026